●○○ low
The assessment is on hold, awaiting a build-up of confirmed evidence.= non-additive meter
Heartseed Inc.: Taking on a cure for severe heart failure with iPS-derived “cardiac spheroids”. The world's leading cause of death is heart disease, and foremost among it is heart failure (HFrEF), in which the left ventricle's contractile power declines. The only cure is a heart transplant, but donors are scarce and only a tiny fraction are saved — to cross this wall, Heartseed takes on regenerative medicine that “supplements” the heart with cardiac muscle made from iPS cells. It was founded in 2015 by Keiichi Fukuda of Keio University's department of cardiology. The hard part was purification. If undifferentiated cells remain in the process of differentiating iPS cells into cardiac muscle, tumors may form after transplantation. Fukuda and colleagues focused on a difference: iPS cells multiply on glucose, but cardiac muscle cells can use lactate for energy. Removing glucose from the medium and adding lactate killed only the undifferentiated cells, and cardiac muscle cells survived. They advance clinical trials (the Phase 1/2 LAPiS trial) of the treatment HS-001, which transplants spheres of such cardiac muscle (“cardiac spheroids”) into the heart, and completed dosing of the planned 10 cases at the end of January 2025. At present independent evidence is scarce, so the assessment is on hold. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q2; estimate based on public information.)
Main narrative
The world's leading cause of death is heart disease, and foremost among it is heart failure (HFrEF), in which the left ventricle's contractile power declines. The only cure is a heart transplant, but donors are scarce and only a tiny fraction are saved — to cross this wall, Heartseed takes on regenerative medicine that “supplements” the heart with cardiac muscle made from iPS cells. It was founded in 2015 by Keiichi Fukuda of Keio University's department of cardiology.
The hard part was purification. If undifferentiated cells remain in the process of differentiating iPS cells into cardiac muscle, tumors may form after transplantation. Fukuda and colleagues focused on a difference: iPS cells multiply on glucose, but cardiac muscle cells can use lactate for energy. Removing glucose from the medium and adding lactate killed only the undifferentiated cells, and cardiac muscle cells survived. They advance clinical trials (the Phase 1/2 LAPiS trial) of the treatment HS-001, which transplants spheres of such cardiac muscle (“cardiac spheroids”) into the heart, and completed dosing of the planned 10 cases at the end of January 2025.
One person’s story (N1)
+ before → after
A trial is underway transplanting iPS-derived cardiac spheroids into patients with severe heart failure who could previously be saved only by a heart transplant. Of four cases with consolidated data, three — excluding one where a non-transplanted area worsened — showed results such as improved cardiac pump function, it is said. But this is a small-case trial stage, and reaching patients as an approved treatment lies ahead.
Source nature: Business Insider Japan / P2 major media. Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- Won many awards, including the Minister of State for Science and Technology Policy Award at the Japan Venture Awards 2021, the MEXT Minister's Award at the University-Originated Venture Awards 2021, the IP BASE AWARD Grand Prix, and the Startup Award at the 7th Japan R&D Medical Awards.P1 cert/award/academic/international body / 中小機構 ほか
− effects (confirmed)
- No confirmed −.
- Trial progress and approval; long-term efficacy and safety
A second look
HS-001 is still at the Phase 1/2 trial stage, and whether it becomes an approved treatment with established efficacy and safety lies ahead. A distance remains between the story of “a fundamental cure for severe heart failure” and outcomes actually reaching protected stakeholders (patients), so the assessment is on hold for now.
Sources
How to read this assessment
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q2 | Back to top